JP2021101720A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021101720A5 JP2021101720A5 JP2021053470A JP2021053470A JP2021101720A5 JP 2021101720 A5 JP2021101720 A5 JP 2021101720A5 JP 2021053470 A JP2021053470 A JP 2021053470A JP 2021053470 A JP2021053470 A JP 2021053470A JP 2021101720 A5 JP2021101720 A5 JP 2021101720A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- sequence shown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 151
- 239000000427 antigen Substances 0.000 claims description 61
- 102000036639 antigens Human genes 0.000 claims description 61
- 108091007433 antigens Proteins 0.000 claims description 61
- 239000012634 fragment Substances 0.000 claims description 61
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 26
- 108010074864 Factor XI Proteins 0.000 claims description 26
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 20
- 230000004913 activation Effects 0.000 claims description 12
- 102100030563 Coagulation factor XI Human genes 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 6
- 108010076282 Factor IX Proteins 0.000 claims description 6
- 108010080805 Factor XIa Proteins 0.000 claims description 6
- 229960004222 factor ix Drugs 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000001605 fetal effect Effects 0.000 claims description 4
- 230000002538 fungal effect Effects 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 230000009424 thromboembolic effect Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 230000004988 N-glycosylation Effects 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 description 13
- 238000007792 addition Methods 0.000 description 11
- 238000012217 deletion Methods 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349888P | 2016-06-14 | 2016-06-14 | |
| US62/349,888 | 2016-06-14 | ||
| JP2018565042A JP7022081B2 (ja) | 2016-06-14 | 2017-06-12 | 抗凝固因子ｘｉ抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565042A Division JP7022081B2 (ja) | 2016-06-14 | 2017-06-12 | 抗凝固因子ｘｉ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021101720A JP2021101720A (ja) | 2021-07-15 |
| JP2021101720A5 true JP2021101720A5 (enExample) | 2021-08-26 |
| JP7277500B2 JP7277500B2 (ja) | 2023-05-19 |
Family
ID=59078269
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565042A Active JP7022081B2 (ja) | 2016-06-14 | 2017-06-12 | 抗凝固因子ｘｉ抗体 |
| JP2021053470A Active JP7277500B2 (ja) | 2016-06-14 | 2021-03-26 | 抗凝固因子ｘｉ抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565042A Active JP7022081B2 (ja) | 2016-06-14 | 2017-06-12 | 抗凝固因子ｘｉ抗体 |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US10676536B2 (enExample) |
| EP (1) | EP3469002A1 (enExample) |
| JP (2) | JP7022081B2 (enExample) |
| KR (2) | KR102379580B1 (enExample) |
| CN (2) | CN109476758B (enExample) |
| AR (1) | AR108717A1 (enExample) |
| AU (3) | AU2017286432B2 (enExample) |
| BR (1) | BR112018075858A2 (enExample) |
| CA (2) | CA3025869C (enExample) |
| CL (2) | CL2018003565A1 (enExample) |
| CO (1) | CO2018013434A2 (enExample) |
| CR (1) | CR20180583A (enExample) |
| DO (1) | DOP2018000284A (enExample) |
| EA (1) | EA201892716A1 (enExample) |
| EC (1) | ECSP18091593A (enExample) |
| GE (2) | GEAP202114983A (enExample) |
| IL (2) | IL263272B2 (enExample) |
| JO (1) | JOP20180121A1 (enExample) |
| MA (1) | MA45234A (enExample) |
| MX (2) | MX2018015757A (enExample) |
| MY (1) | MY201852A (enExample) |
| NI (1) | NI201800134A (enExample) |
| PE (1) | PE20190416A1 (enExample) |
| PH (1) | PH12018502586A1 (enExample) |
| SG (2) | SG10202103120UA (enExample) |
| TN (1) | TN2018000417A1 (enExample) |
| TW (2) | TWI802193B (enExample) |
| UA (1) | UA129793C2 (enExample) |
| WO (1) | WO2017218371A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY36751A (es) | 2015-06-26 | 2017-01-31 | Novartis Ag | Anticuerpos de factor xi y métodos de uso |
| TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| MY201852A (en) * | 2016-06-14 | 2024-03-20 | Merck Sharp & Dohme Llc | Anti-coagulation factor xi antibodies |
| BR112019012667A2 (pt) | 2016-12-23 | 2020-02-11 | Novartis Ag | Anticorpos do fator xi e métodos de uso |
| CN110423278B (zh) * | 2019-08-08 | 2020-07-17 | 上海博槿生物科技有限公司 | 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用 |
| KR20230034361A (ko) * | 2020-07-02 | 2023-03-09 | 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 | 항-fxi/fxia 항체, 이의 항원-결합 단편, 및 이의 약제학적 용도 |
| KR20230035079A (ko) * | 2020-07-03 | 2023-03-10 | 수조우 알파맵 씨오., 엘티디. | 응고인자 xi(fxi) 결합 단백질 |
| AU2022219476A1 (en) * | 2021-02-09 | 2023-09-21 | Arxx Therapeutics As | Anti-s100a4 humanized antibodies, uses and methods |
| EP4442273A4 (en) * | 2021-11-30 | 2025-12-24 | Suzhou Alphamab Co Ltd | METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOEMBOLIC DISEASES |
| EP4644426A1 (en) * | 2022-12-30 | 2025-11-05 | Gan & Lee Pharmaceuticals Co., Ltd. | Antibody against coagulation factor xi and/or activated form factor xia thereof, and use thereof |
| WO2025130748A1 (zh) * | 2023-12-22 | 2025-06-26 | 四川科伦博泰生物医药股份有限公司 | 一种抗凝血因子XI/XIa抗体制剂 |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| WO1989012463A1 (en) | 1988-06-21 | 1989-12-28 | Genentech, Inc. | Method and therapeutic compositions for the treatment of myocardial infarction |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| JPH0656382A (ja) | 1992-08-04 | 1994-03-01 | Kawasaki Steel Corp | コークス乾式消火装置のバケット巻上機の吊ビーム装置 |
| MA24512A1 (fr) | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
| GB9818110D0 (en) | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
| US6096002A (en) | 1998-11-18 | 2000-08-01 | Bioject, Inc. | NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method |
| EP1135415B1 (en) | 1998-12-01 | 2010-08-11 | Facet Biotech Corporation | Humanized antibodies to gamma-interferon |
| EP1259615B1 (en) | 2000-03-03 | 2008-11-12 | Cambridge Antibody Technology Limited | Antibodies against eotaxin and their use |
| TWI338009B (en) * | 2001-10-29 | 2011-03-01 | Genentech Inc | Antibodies for inhibiting blood coagulation and methods of use thereof |
| AU2003210060B2 (en) | 2002-03-22 | 2010-02-25 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| MEP31508A (hr) | 2003-07-15 | 2010-10-10 | Amgen Inc | Humana anti-ngf neutrališuća antitijela kao selektivni ihibitori ngf signalne kaskade |
| EA016022B1 (ru) | 2004-12-21 | 2012-01-30 | Сентокор, Инк. | Выделенное антитело млекопитающего против il-12 и способ изменения его активности |
| US8318906B2 (en) | 2005-04-15 | 2012-11-27 | The Regents Of The University Of California | EMP2 antibodies and their therapeutic uses |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| EP1960434B1 (en) | 2005-12-08 | 2012-07-11 | Medarex, Inc. | Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 |
| AU2006321841C1 (en) | 2005-12-08 | 2013-01-24 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to protein tyrosine kinase 7 ( PTK7 ) and their use |
| MX2008014978A (es) | 2006-06-06 | 2008-12-09 | Crucell Holland Bv | Moleculas de union humanas que tienen actividad exterminadora contra enterococos y staphylococcus aureus y usos de las mismas. |
| KR20090039739A (ko) | 2006-08-03 | 2009-04-22 | 아스트라제네카 아베 | αＶβ６에 대해 작용하는 항체 및 그의 용도 |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| WO2009008916A2 (en) | 2007-03-22 | 2009-01-15 | The Regents Of The University Of Californina | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| GB0708585D0 (en) | 2007-05-03 | 2007-06-13 | Queen Mary & Westfield College | Novel antibody and use in diagnosis and therapy of arthropathies |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| EP3124497B1 (en) | 2007-09-14 | 2020-04-15 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
| AU2008303796B2 (en) | 2007-09-26 | 2014-09-18 | Amgen Inc. | Heparin-binding epidermal growth factor-like growth factor antigen binding proteins |
| AU2016203944A1 (en) | 2007-11-21 | 2016-07-07 | Oregon Health & Science University | Anti-factor xi monoclonal antibodies and methods of use thereof |
| ES2566963T3 (es) | 2007-11-21 | 2016-04-18 | Oregon Health & Science University | Anticuerpos monoclonales anti-factor XI y métodos de uso de los mismos |
| US8188235B2 (en) | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
| WO2009154461A1 (en) | 2008-06-19 | 2009-12-23 | Prothix Bv | Use of anti-factors xi antibodies for prevention of thrombus formation |
| CA2732003A1 (en) | 2008-07-31 | 2010-02-04 | James D. Marks | Antibodies that neutralize botulinum neurotoxins |
| EA201500316A1 (ru) | 2008-10-31 | 2016-01-29 | Сентокор Орто Байотек Инк. | Антагонисты толл-подобного рецептора 3 |
| WO2010054007A1 (en) | 2008-11-07 | 2010-05-14 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| LT2373691T (lt) | 2008-12-18 | 2019-05-27 | Oregon Health & Science University | Anti-fxi antikūnai ir jų panaudojimo būdai |
| JP2012513194A (ja) | 2008-12-23 | 2012-06-14 | アストラゼネカ アクチボラグ | α５β１に向けられた標的結合剤およびその使用 |
| EP3385279B1 (en) | 2009-03-20 | 2020-02-26 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| AU2010236256C1 (en) | 2009-04-16 | 2015-10-22 | Abbvie Biotherapeutics Inc. | Anti-TNF-alpha antibodies and their uses |
| JP5694923B2 (ja) | 2009-04-27 | 2015-04-01 | 協和発酵キリン株式会社 | 血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体 |
| EP2488553B1 (en) | 2009-10-12 | 2015-06-17 | Pfizer Inc. | Cancer treatment |
| EP2496600A1 (en) | 2009-11-04 | 2012-09-12 | Fabrus LLC | Methods for affinity maturation-based antibody optimization |
| US9045536B2 (en) | 2009-12-23 | 2015-06-02 | Merck Sharp & Dohme Corp. | Cell line 3M |
| EP2532151A2 (en) * | 2010-02-03 | 2012-12-12 | Trilogy IP Holdings, Inc. | Mobile communication plan offerings |
| KR102024922B1 (ko) | 2010-07-16 | 2019-09-25 | 아디맵 엘엘씨 | 항체 라이브러리 |
| CA2815154A1 (en) | 2010-08-06 | 2012-02-09 | U3 Pharma Gmbh | Use of her3 binding agents in prostate treatment |
| AR084141A1 (es) | 2010-11-19 | 2013-04-24 | Imai Toshio | Anticuerpos neutralizadores anti-ccl20 |
| IL269565B2 (en) | 2011-01-06 | 2024-06-01 | Dyax Corp | Plasma kallikrein binding proteins |
| AU2012236068A1 (en) | 2011-04-01 | 2013-10-17 | Eureka Therapeutics, Inc. | T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2 |
| PL2718322T3 (pl) | 2011-06-06 | 2019-07-31 | Novo Nordisk A/S | Lecznicze przeciwciała |
| US8765385B2 (en) | 2011-10-27 | 2014-07-01 | Ravindra Kumar | Method of detection of neutralizing anti-actriib antibodies |
| PL2650310T3 (pl) | 2012-04-13 | 2017-01-31 | Rottapharm Biotech S.R.L. | Przeciwciało przeciw-ADAMTS-5, jego pochodne i zastosowania |
| BR112014027952B1 (pt) | 2012-05-10 | 2022-06-21 | Bayer Pharma Aktiengesellschaft | Anticorpos monoclonais humanos capazes de se ligarem ao fator de coagulação xi, seu uso, composição farmacêutica e medicamento os compreendendo, ácido nucleico que o codifica, bem como vetor |
| CN104918956A (zh) | 2012-05-17 | 2015-09-16 | 索伦托治疗有限公司 | 与egfr结合的抗原结合蛋白 |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| US20160319032A1 (en) | 2013-10-01 | 2016-11-03 | Medlmmune Limited | Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer |
| EP3121273A4 (en) | 2014-03-20 | 2017-08-30 | Japan As Represented By Director-General Of National Institute Of Infectious Diseases | Antibody having infection-inhibiting activity against hepatitis c virus |
| NZ726911A (en) | 2014-06-03 | 2023-01-27 | Xbiotech Inc | Compositions and methods for treating and preventing staphylococcus aureus infections |
| SG10201913611QA (en) | 2014-08-08 | 2020-03-30 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| EP3991748A3 (en) | 2015-04-07 | 2022-08-24 | Alector LLC | Anti-sortilin antibodies and methods of use thereof |
| US11174313B2 (en) | 2015-06-12 | 2021-11-16 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
| UY36751A (es) | 2015-06-26 | 2017-01-31 | Novartis Ag | Anticuerpos de factor xi y métodos de uso |
| US11066481B2 (en) | 2015-07-23 | 2021-07-20 | The Regents Of The University Of California | Antibodies to coagulation factor XIa and uses thereof |
| JP7628764B2 (ja) | 2015-09-29 | 2025-02-12 | アムジエン・インコーポレーテツド | Ａｓｇｒ阻害剤 |
| RU2021129189A (ru) | 2016-01-22 | 2021-11-15 | Мерк Шарп И Доум Корп. | Антитела против фактора свертывания xi |
| MY201852A (en) | 2016-06-14 | 2024-03-20 | Merck Sharp & Dohme Llc | Anti-coagulation factor xi antibodies |
| EP4413996A3 (en) | 2016-09-20 | 2024-10-23 | Aronora, Inc. | Novel antibodies against factor xi and uses thereof |
-
2017
- 2017-06-12 MY MYPI2018002406A patent/MY201852A/en unknown
- 2017-06-12 CN CN201780037421.3A patent/CN109476758B/zh active Active
- 2017-06-12 SG SG10202103120UA patent/SG10202103120UA/en unknown
- 2017-06-12 CA CA3025869A patent/CA3025869C/en active Active
- 2017-06-12 EP EP17731444.0A patent/EP3469002A1/en active Pending
- 2017-06-12 AU AU2017286432A patent/AU2017286432B2/en active Active
- 2017-06-12 EA EA201892716A patent/EA201892716A1/ru unknown
- 2017-06-12 AR ARP170101603A patent/AR108717A1/es unknown
- 2017-06-12 SG SG11201810763TA patent/SG11201810763TA/en unknown
- 2017-06-12 TW TW110149482A patent/TWI802193B/zh active
- 2017-06-12 JP JP2018565042A patent/JP7022081B2/ja active Active
- 2017-06-12 CN CN202310501882.9A patent/CN116425879A/zh active Pending
- 2017-06-12 GE GEAP202114983A patent/GEAP202114983A/en unknown
- 2017-06-12 MX MX2018015757A patent/MX2018015757A/es unknown
- 2017-06-12 CR CR20180583A patent/CR20180583A/es unknown
- 2017-06-12 BR BR112018075858-2A patent/BR112018075858A2/pt active Search and Examination
- 2017-06-12 TN TNP/2018/000417A patent/TN2018000417A1/en unknown
- 2017-06-12 UA UAA201900311A patent/UA129793C2/uk unknown
- 2017-06-12 IL IL263272A patent/IL263272B2/en unknown
- 2017-06-12 KR KR1020217004608A patent/KR102379580B1/ko active Active
- 2017-06-12 TW TW106119391A patent/TWI752964B/zh active
- 2017-06-12 US US15/619,620 patent/US10676536B2/en active Active
- 2017-06-12 KR KR1020197001266A patent/KR102218714B1/ko active Active
- 2017-06-12 CA CA3172367A patent/CA3172367A1/en active Pending
- 2017-06-12 MA MA045234A patent/MA45234A/fr unknown
- 2017-06-12 GE GEAP201714983A patent/GEP20227382B/en unknown
- 2017-06-12 IL IL315266A patent/IL315266A/en unknown
- 2017-06-12 WO PCT/US2017/036940 patent/WO2017218371A1/en not_active Ceased
- 2017-06-12 PE PE2018003203A patent/PE20190416A1/es unknown
- 2017-06-16 JO JOP/2018/0121A patent/JOP20180121A1/ar unknown
-
2018
- 2018-12-06 PH PH12018502586A patent/PH12018502586A1/en unknown
- 2018-12-10 NI NI201800134A patent/NI201800134A/es unknown
- 2018-12-11 EC ECSENADI201891593A patent/ECSP18091593A/es unknown
- 2018-12-11 CL CL2018003565A patent/CL2018003565A1/es unknown
- 2018-12-12 CO CONC2018/0013434A patent/CO2018013434A2/es unknown
- 2018-12-13 DO DO2018000284A patent/DOP2018000284A/es unknown
- 2018-12-14 MX MX2023012740A patent/MX2023012740A/es unknown
-
2020
- 2020-05-01 US US16/864,583 patent/US11479615B2/en active Active
- 2020-05-01 US US16/864,570 patent/US11512142B2/en active Active
- 2020-05-01 US US16/864,577 patent/US11485794B2/en active Active
- 2020-05-01 US US16/864,559 patent/US11661460B2/en active Active
- 2020-07-30 AU AU2020210233A patent/AU2020210233B2/en active Active
-
2021
- 2021-03-26 JP JP2021053470A patent/JP7277500B2/ja active Active
-
2023
- 2023-04-18 US US18/302,033 patent/US12275800B2/en active Active
-
2024
- 2024-02-06 CL CL2024000367A patent/CL2024000367A1/es unknown
- 2024-02-20 AU AU2024201084A patent/AU2024201084A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6944509B2 (ja) | Ｉｌ−１８結合分子 | |
| JP2025016349A5 (enExample) | ||
| US20220289858A1 (en) | Anti-cd40 antibodies and uses thereof | |
| RU2495050C2 (ru) | Связующий элемент для рецептора gm-csf | |
| AU2008243049B2 (en) | Novel compounds | |
| AU2011289629B2 (en) | Anti-N3pGlu amyloid beta peptide antibodies and uses thereof | |
| CA2914170C (en) | Interleukin-13 binding proteins | |
| RU2429245C2 (ru) | Иммуноглобулины | |
| JP2022031635A5 (enExample) | ||
| IL315266A (en) | Anti-coagulation factor xi antibodies | |
| TWI699376B (zh) | 抗cd40抗體、其抗原結合片段及其醫藥用途 | |
| US20140212423A1 (en) | Blood-brain barrier penetrating dual specific binding proteins | |
| RU2014151788A (ru) | Молекула, специфически связывающаяся с rsv | |
| JP2007530068A5 (enExample) | ||
| RU2007132020A (ru) | Партнеры специфического связывания с ngf | |
| EA039946B1 (ru) | Антитела-антагонисты к интерферону альфа и интерферону омега | |
| JP2008527989A5 (enExample) | ||
| JP2021534797A5 (enExample) | ||
| KR20120098587A (ko) | 폴리펩티드 및 치료 방법 | |
| US20110223176A1 (en) | Basigin binding proteins | |
| JP7060906B2 (ja) | 抗ｉｌ－５抗体 | |
| AU2016404449B2 (en) | Trispecific antibodies against IL-17A, IL-17F and another proinflammatory molecule | |
| WO2022026775A1 (en) | Compositions and methods for targeting coronavirus | |
| AU2014233615B2 (en) | Anti-N3pGlu Amyloid Beta Peptide Antibodies And Uses Thereof | |
| RU2022115671A (ru) | Моноклональное антитело или его антигенсвязывающий фрагмент, которое специфически связывается с BCMA, и его применение |